ASP Isotopes Inc. (ASPI), a Dallas-based development-stage advanced materials company, carries a limited but bullish sell-side following. Three current targets were reviewed: Canaccord Genuity's $11, Cantor Fitzgerald's $13 (initiated in December 2025 and reiterated in January 2026), and Lucid Capital Markets' $15 (initiated in October 2025). The simple average is $13.00, rounded to $13, with a range of $11 to $15.
That spread is unusually wide relative to the share price and signals divergent views on timing rather than direction. All three firms rate the shares a Buy, yet the lower targets reflect caution about how quickly pre-revenue programs can convert to dependable cash flow. Importantly, several of these targets were set when the stock traded well above current levels, and they have not yet fully caught up with the 2026 selloff — a point data providers flag explicitly.
As of mid-October 2026, ASPI trades near $2.14, down sharply from its 52-week highs and well below its 50-day and 200-day moving averages. Reaching $13 would require an advance of roughly 500%, which must be characterized as a very large move. A path of that magnitude would depend less on near-term earnings and more on the market re-rating the company as a credible, multi-product supplier of scarce isotopes and industrial gases.
Fundamentals remain pre-profit: trailing twelve-month revenue is about $30.9 million against a net loss near $151.6 million, though the company held roughly $254.9 million in cash as of mid-2026. The company's own long-term framework targets EBITDA (earnings before interest, taxes, depreciation, and amortization) above $300 million by 2031 — a goal that, if approached, would reframe the entire valuation debate.
Revenue momentum is real. Second-quarter 2026 revenue rose roughly 328% year over year to about $5.1 million, and the net loss narrowed. The company is advancing several commercial milestones: first helium and LNG deliveries from the Virginia Gas Project in South Africa, initial shipments of enriched Silicon-28, Ytterbium-176, and Carbon-14, and a growing PET Labs radiopharmacy business expected to generate more than $14 million of revenue in 2026. The Quantum Leap Energy unit is building a nuclear-fuel platform around HALEU (high-assay low-enriched uranium) and Lithium-6, and the company has announced collaborations and memoranda of understanding with advanced nuclear developers.
The counterweights are substantial. The company remains deeply unprofitable and is not forecast to reach breakeven for several years. Shareholder dilution has been significant — the share count rose about 75% in a recent year, partly from a debt-for-equity exchange tied to Quantum Leap Energy convertible notes. ASPI has also delayed SEC filings, including its 10-K and 10-Q, which can weigh on investor confidence and financing. Some independent research models a fair value well below the current price, underscoring how much of the bull case rests on execution that has not yet been proven at scale.
The technical picture is weak. ASPI trades below both its 50-day and 200-day moving averages and has been in an extended downtrend, with a 52-week low near $2.03 acting as the nearest major support level. The stock's prior 52-week highs above $11 represent a distant resistance zone, with the psychological $5 and $10 levels likely to act as intermediate hurdles on any sustained recovery. Momentum indicators have signaled oversold conditions at times, but oversold markets can remain so for extended periods.
Analyst price targets conventionally reflect a roughly 12-month outlook, though the exact horizons behind these three targets are not uniformly disclosed and may differ. Investors should monitor helium and LNG commissioning milestones, first commercial isotope shipments, quarterly revenue growth and cash burn, any new capital raises or further dilution, and resolution of the delayed regulatory filings. Developments around Quantum Leap Energy's nuclear-fuel partnerships and the proposed Noble Africa transaction are also central to the narrative.
For traders navigating a volatile name like ASPI, Tickeron's AI Daily Buy/Sell Signals can provide an additional layer of context. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone.
The $13 central target is a genuine analyst-derived figure — the simple average of three verified targets — but it is built on a view of ASP Isotopes that predates much of the stock's recent decline. Reaching it would require a roughly 500% advance, a very large move that hinges on converting early commercial progress into sustained, scaled revenue and cash flow. The supporting factors are tangible: fast revenue growth, a substantial cash position, and multiple businesses approaching commercial delivery. The obstacles are equally concrete: continued losses, dilution, delayed filings, and a wide gap between current fundamentals and the company's 2031 EBITDA ambitions. The $11 to $15 target range reflects honest uncertainty about how quickly execution will materialize. Investors should weigh that uncertainty carefully rather than treating the average as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ASPI has been loosely correlated with LWLG. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPI jumps, then LWLG could also see price increases.
| Ticker / NAME | Correlation To ASPI | 1D Price Change % | ||
|---|---|---|---|---|
| ASPI | 100% | -5.16% | ||
| LWLG - ASPI | 40% Loosely correlated | +3.71% | ||
| GEVO - ASPI | 38% Loosely correlated | +3.31% | ||
| ESI - ASPI | 35% Loosely correlated | -3.19% | ||
| ALB - ASPI | 32% Poorly correlated | -2.43% | ||
| SQM - ASPI | 30% Poorly correlated | -3.05% | ||
More | ||||